secwatch.observer — SEC 8-K summary
======================================

Issuer:     SS Innovations International, Inc. (SSII)
CIK:        0001676163
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001213900-25-043384
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SS Innovations Q1 revenue $5.1M (+40.8% YoY); net loss narrows; FDA submission planned by July 2025
--------------------------------------------------------------------------------

- Revenue $5.1M (+40.8% YoY); gross margin 21.23% (up 121 bps); net loss $5.7M ($0.03 diluted) vs $9.8M ($0.06) in Q1 2024.
- SSi Mantra installations 15 in Q1 (+66.7%), cumulative installed base 78, cumulative surgeries 3,568.
- Cash $15.9M, zero long-term debt; subsequently uplisted to Nasdaq on April 25, 2025.
- Plan to submit De Novo FDA application for SSi Mantra by July 2025; CE Mark possible late 2025.
- Achieved world's first robotic cardiac telesurgery; gained regulatory approvals in Philippines and Ukraine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1676163/000121390025043384/0001213900-25-043384-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1676163/000121390025043384/ea0242229-8k_ssinnov.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-043384

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer